HIFU is a noninvasive local treatment that uses thermal energy to ablate prostate cancer lesions. Long-term results for tumor control and oncologic outcomes are sparse, according to researchers at Stanford University in California.
Postdoctoral nuclear medicine fellow Dr. Heying Duan will discuss a novel approach in 14 men with newly diagnosed prostate cancer who underwent focal ablation with HIFU. The researchers performed imaging with either gallium-68 PSMA-PET/MRI prior to surgery, followed by gallium-68 RM2 PET/MRI within two weeks, or vice versa.
Preliminary results showed that both Ga-68 PSMA and Ga-68 RM2 PET/MRI identified the dominant lesion for HIFU ablation prior to treatment and accurately verified response to treatment in 88.9% of patients.
Check out this session for the details and a discussion of next steps.